Overt Hepatic Encephalopathy Market Company Profiles, Market Segments, Landscape 2027
Overt
Hepatic Encephalopathy Market is expected to register 11.2% CAGR during the
forecast period of 2019 to 2025 and held a market value of USD 54.28 Million in
2018.Hepatic encephalopathy is a disorder that occurs by a buildup of toxins in
the brain which cause advance liver disease. People affected with hepatic
encephalopathy get changed in their behavior, mood, speech, sleep, or the way
they move. On the base of severity, hepatic encephalopathy is divided into two
broad categories that is covert hepatic encephalopathy and overt hepatic encephalopathy.
Overt hepatic encephalopathy (OHE) is the condition which is associated with
increasing rates of hospitalizations and mortality, and poor quality of life.
40% of patients with cirrhosis during their clinical care develop overt hepatic
encephalopathy.
The factors that causes overt hepatic encephalopathy during
advanced liver disease are infected, gastrointestinal bleeding, metabolic
disturbance, and receipt of sedative medications. According to the U.S.
National Library of Medicine, 30-50% of patient with cirrhosis have a chance to
develop overt hepatic encephalopathy. Additionally, owing to overt hepatic
encephalopathy, there is the negative impact on the health related quality of
life of the patient.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/764
Global Overt hepatic encephalopathy Market – Overview
The global overt hepatic encephalopathy market is showing
the moderate growth; mainly due to increase in patient population suffering
with cirrhosis disease. Moreover, increase in consumption of alcohol also
increase the prevalence of cirrhosis around the globe. According to World
Health Organization (WHO), Alcohol consumption causes 20% to 50% of cirrhosis
disease, epilepsy, poisonings, road traffic accidents, violence and several
types of cancer.
Companies are showing much interest toward the overt hepatic
encephalopathy market, as they feel there are huge opportunities and gaps
between the market demand and supply of effective treatment. Liver transplant
is the major cure consider in the treatment of overt hepatic encephalopathy.
Thus, there is the lot of scope for companies to introduce better drugs which
help to cure the disease. However, XIFAXAN 550, the drug in the market for the
treatment of overt hepatic encephalopathy but they have few limitation, which
generate the demand for a cost effective treatment. According to World Health
Organization, (WHO), in 2015, around 887 000 deaths occurs globally, mostly
from complications from cirrhosis and hepatocellular carcinoma. Report also
suggest that, in some people, the hepatitis B virus can also cause a chronic
liver infection that can later develop into cirrhosis, which turm into liver cancer.
Many companies such as, Alfa Wassermann S.p.A, Cosmo
Pharmaceuticals S.p.A, KannaLife Sciences Inc., Ocer Therapeutics, Inc.,
Rebiotix Inc., Spherium Biomed S.L., and Umecrine Cognition AB are working to
introduce best treatment in the market. All these development help market to
get quality treatment and fulfill unmet requirement.
Global Overt hepatic encephalopathy Market - Regional
Analysis
The market of overt hepatic encephalopathy is much higher in
the Americas region. There is huge population suffering with liver diseases.
According to reports published by the Centers for Disease Control and
Prevention (CDC) in 2016, around 3.9 million people are diagnosed with liver
disease that is approx. 1.6% of adults in the United States. Additionally, report
suggests that 38,170 deaths occur owing to liver disease. Increase in
prevalence of overt hepatic encephalopathy with increasing demand for the
better treatment has boosted the growth of the market.
Europe is also considered a huge market for overt hepatic
encephalopathy players, owing to the increasing prevalence of overt hepatic
encephalopathy, increasing government support, and well developed technology.
Moreover, increase in the incidence of high overt hepatic encephalopathy owing
to consumption of alcohol also fuelling the growth of the market.
Asia Pacific and the Middle East and Africa region are
considering the big market. Whereas, countries like India and China of Asia
Pacific region are considered to be the fastest growing region due to the
presence of huge population suffering with overt hepatic encephalopathy,
additionally they are open to adopt new treatment option from a developed
country, this gap between the developed and developing countries present
significant growth opportunities for the overt hepatic encephalopathy market
players in the coming years. Whereas, the Middle East and Africa are the low
growing market due to his incapability of investment.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/overt-hepatic-encephalopathy-market-764
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to
unravel the complexity of various industries through our Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR
team have supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Email: sales@marketresearchfuture.com
Comments
Post a Comment